Palatin Technologies, Inc. (PTN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | -0 | 1 | 5 | 4 | 0 | 13 | 14 |
| Operating profit | $m | -17 | -7 | ||||||
| Net profit | $m | -22 | -34 | -36 | -24 | -30 | -17 | -6 | -1 |
| EPS reported | $ | -32.15 | -4.16 | ||||||
| Operating cashflow per share | $ | -39.58 | -15.37 | ||||||
| Capex per share | $ | 0.00 | 0.05 | ||||||
| FCF per share | $ | -39.58 | -15.42 | ||||||
| Free cash flow | $m | -21 | -15 | ||||||
| Net debt | $m | -3 | -10 | ||||||
| Book value equity | $m | -5 | 11 | ||||||
| Book value per share | $ | -8.87 | 9.64 | ||||||
| Number of shares | m | 0.54 | 1.1 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.79 | 0.36 | ||||||
| P/S LTM | x | 0.00 | 0.29 | ||||||
| P/FCF LTM | x | -0.18 | -0.25 | ||||||
| EV/EBITDA LTM | x | -0.08 | -0.22 | ||||||
| EV/Sales LTM | x | 0.00 | 0.53 | ||||||
| Earnings Yield LTM | % | -4.59% | -68.71% | ||||||
| FCF Yield | % | -565.40% | -397.61% | ||||||
| Quality | |||||||||
| ROE | % | +362.30% | -141.40% | ||||||
| ROIC | % | +3.78% | -59.93% | ||||||
| Operating margin | % | 0.00% | -50.60% | ||||||
| Gross margin | % | 0.00% | +99.76% | ||||||
| FCF/Sales | % | - | -116.29% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -100.00% | +186.95% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -130.09 | -52.27 | ||||||
| Net Debt/EBITDA | x | 0.14 | 1.61 | ||||||
| EBIT/Net interest | x | -1,162.06 | -898.59 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | 0.54 | -0.96 | ||||||
| Gross debt/equity | x | -0.03 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free